DGIdb - AMPHETAMINE Drug Record

AMPHETAMINE chembl:CHEMBL405 Approved

Alternate Names:

ADZENYS ER
AMFETAMINE
AMPHETAMINE RESIN COMPLEX
NSC-27159
DYANAVEL XR
AMPHETAMINE
ADZENYS XR-ODT

Drug Info:

Drug Class	central nervous system stimulants
Year of Approval	approved before 1982
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	for treatment of cognitive dysfunction,for treatment of ADHD

(4 More Sources)

Publications:

Galici et al., 2003, Selective decreases in amphetamine self-administration and regulation of dopamine transporter function in diabetic rats., Neuroendocrinology
Garcia et al., 2005, Akt is essential for insulin modulation of amphetamine-induced human dopamine transporter cell-surface redistribution., Mol. Pharmacol.
Fone et al., 2005, Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder., Curr Opin Pharmacol
Lott et al., 2005, Dopamine transporter gene associated with diminished subjective response to amphetamine., Neuropsychopharmacology
Madras et al., 2005, The dopamine transporter and attention-deficit/hyperactivity disorder., Biol. Psychiatry
Miller et al., 2005, Primate trace amine receptor 1 modulation by the dopamine transporter., J. Pharmacol. Exp. Ther.
Kahlig et al., 2005, Amphetamine induces dopamine efflux through a dopamine transporter channel., Proc. Natl. Acad. Sci. U.S.A.
Innis et al., 1992, Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates., Synapse
Scruggs et al., 2005, Cocaine- and amphetamine-regulated transcript peptide potentiates spinal glutamatergic sympathoexcitation in anesthetized rats., Regul. Pept.
Loos et al., 2005, Melanocortin-4 receptor gene and physical activity in the Québec Family Study., Int J Obes (Lond)
Vicentic et al., 2006, The CART receptors: background and recent advances., Peptides
McAlister et al., 2004, Effect of leptin administration versus re-feeding on hypothalamic neuropeptide gene expression in fasted male rats., Can. J. Physiol. Pharmacol.
Mühlhäusler et al., 2005, Impact of glucose infusion on the structural and functional characteristics of adipose tissue and on hypothalamic gene expression for appetite regulatory neuropeptides in the sheep fetus during late gestation., J. Physiol. (Lond.)
Oliveira et al., 2005, Leptin fragments induce Fos immunoreactivity in rat hypothalamus., Regul. Pept.
Wu et al., 1997, Interactions of amphetamine analogs with human liver CYP2D6., Biochem. Pharmacol.
Xie et al., 2007, Rhesus monkey trace amine-associated receptor 1 signaling: enhancement by monoamine transporters and attenuation by the D2 autoreceptor in vitro., J. Pharmacol. Exp. Ther.
Reese et al., 2007, Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine., J. Pharmacol. Exp. Ther.
Xie et al., 2007, Trace amine-associated receptor 1 is a modulator of the dopamine transporter., J. Pharmacol. Exp. Ther.
Wolinsky et al., 2007, The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia., Genes Brain Behav.
Eiden et al., 2011, VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse., Ann. N. Y. Acad. Sci.
Sulzer et al., 2005, Mechanisms of neurotransmitter release by amphetamines: a review., Prog. Neurobiol.
Teng et al., 1998, Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine., J. Neurochem.
Sulzer et al., 1995, Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport., J. Neurosci.
Heal et al., 2013, Amphetamine, past and present--a pharmacological and clinical perspective., J. Psychopharmacol. (Oxford)
Martin-Iverson et al., 1986, The effects of cysteamine on dopamine-mediated behaviors: evidence for dopamine-somatostatin interactions in the striatum., Pharmacol. Biochem. Behav.
Reisine et al., 1980, Effects of combined administration of amphetamine and iprindole on brain adrenergic receptors., Brain Res.
Leibowitz, 1970, Reciprocal hunger-regulating circuits involving alpha- and beta-adrenergic receptors located, respectively, in the ventromedial and lateral hypothalamus., Proc. Natl. Acad. Sci. U.S.A.
Silva-Araújo et al., 1995, Expression of glial fibrillary acidic protein in the rat retina after exposure to psychostimulants., Retina (Philadelphia, Pa.)
Armstrong et al., 2004, Repeated amphetamine treatment causes a persistent elevation of glial fibrillary acidic protein in the caudate-putamen., Eur. J. Pharmacol.

AMPHETAMINE CARTPT

Interaction Score: 8.32

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name C105, levo-amphetamine sulfate

Novel drug target Established target

PMIDs:
15680473 15597110 16713658 15644956 15661821 15680478

Sources:
TdgClinicalTrial
AMPHETAMINE SLC18A2

Interaction Score: 1.5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name C105, levo-amphetamine sulfate

Novel drug target Established target

Trial Name SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR

PMIDs:
21272013 15955613 9648873 7751968 23539642

Sources:
TdgClinicalTrial
AMPHETAMINE SST

Interaction Score: 1.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2874568

Sources:
NCI
AMPHETAMINE TAAR1

Interaction Score: 1.19

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR

Novel drug target Established target

Trial Name C105, levo-amphetamine sulfate

PMIDs:
17234900 17218486 15764732 17234899 17212650

Sources:
TdgClinicalTrial TTD
AMPHETAMINE SLC6A3

Interaction Score: 1.03

Interaction Types & Directionality:

negative modulator (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Dopamine transporter releasing agent

Trial Name SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR

PMIDs:
12624535 15795321 15661631 15602501 15950014 15764732 15728379

Sources:
TdgClinicalTrial ChemblInteractions NCI TEND
AMPHETAMINE GFAP

Interaction Score: 0.57

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7569352 15044042

Sources:
NCI
AMPHETAMINE KAT2B

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
AMPHETAMINE ADRA1A

Interaction Score: 0.16

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

PMIDs:
6245760 4399738

Sources:
TEND
AMPHETAMINE NAT1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Norepinephrine transporter releasing agent

PMIDs:
None found

Sources:
ChemblInteractions
AMPHETAMINE ADRA2A

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TEND
AMPHETAMINE DRD2

Interaction Score: 0.06

Interaction Types & Directionality:

binder

Interaction Info:

PMIDs:
1532675

Sources:
PharmGKB
AMPHETAMINE OPRM1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
AMPHETAMINE CYP2D6

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9264312

Sources:
NCI PharmGKB FDA

TEND: AMPHETAMINE
- Version: 01-August-2011
Alternate Names:

AMPHETAMINE Primary Drug Name

Drug Info:

Year of Approval approved before 1982

Drug Class central nervous system stimulants

Publications:
TdgClinicalTrial: AMPHETAMINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications for treatment of cognitive dysfunction,for treatment of ADHD

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: AMPHETAMINE

Version: 14-September-2017

Alternate Names:

C28822 NCI drug code

Drug Info:

Publications:

Wu et al., 1997, Interactions of amphetamine analogs with human liver CYP2D6., Biochem. Pharmacol.

Silva-Araújo et al., 1995, Expression of glial fibrillary acidic protein in the rat retina after exposure to psychostimulants., Retina (Philadelphia, Pa.)

Armstrong et al., 2004, Repeated amphetamine treatment causes a persistent elevation of glial fibrillary acidic protein in the caudate-putamen., Eur. J. Pharmacol.

TTD: Amphetamine
- Version: 2020.06.01
Alternate Names:

D05BMG TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL405
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
PharmGKB: amphetamine
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL405
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
FDA: Amphetamine
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Trial Name	C105, levo-amphetamine sulfate
Novel drug target	Established target

Trial Name	SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR
Novel drug target	Established target
Trial Name	C105, levo-amphetamine sulfate

Direct Interaction	yes
Mechanism of Interaction	Dopamine transporter releasing agent
Trial Name	SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR

Direct Interaction	yes
Mechanism of Interaction	Norepinephrine transporter releasing agent

AMPHETAMINE Drug Record

AMPHETAMINE chembl:CHEMBL405 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name C105, levo-amphetamine sulfate Novel drug target Established target

PMIDs: 15680473 15597110 16713658 15644956 15661821 15680478

Sources: TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name C105, levo-amphetamine sulfate Novel drug target Established target Trial Name SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR

PMIDs: 21272013 15955613 9648873 7751968 23539642

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 2874568

Sources: NCI

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR Novel drug target Established target Trial Name C105, levo-amphetamine sulfate

PMIDs: 17234900 17218486 15764732 17234899 17212650

Sources: TdgClinicalTrial TTD

Interaction Types & Directionality: negative modulator (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Dopamine transporter releasing agent Trial Name SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR

PMIDs: 12624535 15795321 15661631 15602501 15950014 15764732 15728379

Sources: TdgClinicalTrial ChemblInteractions NCI TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 7569352 15044042

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: agonist (activating)

Interaction Info:

PMIDs: 6245760 4399738

Sources: TEND

Interaction Types & Directionality: n/a

Interaction Info: Direct Interaction yes Mechanism of Interaction Norepinephrine transporter releasing agent

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TEND

Interaction Types & Directionality: binder

Interaction Info:

PMIDs: 1532675

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9264312

Sources: NCI PharmGKB FDA

TEND: AMPHETAMINE

Alternate Names: AMPHETAMINE Primary Drug Name

Drug Info: Year of Approval approved before 1982 Drug Class central nervous system stimulants

Publications:

TdgClinicalTrial: AMPHETAMINE

Alternate Names:

Drug Info: Drug Indications for treatment of cognitive dysfunction,for treatment of ADHD Drug Class Small Molecule FDA Approval approved

Publications:

NCI: AMPHETAMINE

Alternate Names: C28822 NCI drug code

Drug Info:

TTD: Amphetamine

Alternate Names: D05BMG TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL405

Alternate Names:

Drug Info:

Publications:

PharmGKB: amphetamine

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name C105, levo-amphetamine sulfate

Novel drug target Established target

PMIDs:
15680473 15597110 16713658 15644956 15661821 15680478

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name C105, levo-amphetamine sulfate

Novel drug target Established target

Trial Name SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR

PMIDs:
21272013 15955613 9648873 7751968 23539642

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
2874568

Sources:
NCI

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR

Novel drug target Established target

Trial Name C105, levo-amphetamine sulfate

PMIDs:
17234900 17218486 15764732 17234899 17212650

Sources:
TdgClinicalTrial TTD

Interaction Types & Directionality:

negative modulator (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Dopamine transporter releasing agent

Trial Name SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR

PMIDs:
12624535 15795321 15661631 15602501 15950014 15764732 15728379

Sources:
TdgClinicalTrial ChemblInteractions NCI TEND

Interaction Types & Directionality:

n/a

PMIDs:
7569352 15044042

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

agonist (activating)

PMIDs:
6245760 4399738

Sources:
TEND

Interaction Types & Directionality:

n/a

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Norepinephrine transporter releasing agent

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TEND

Interaction Types & Directionality:

binder

PMIDs:
1532675

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
9264312

Sources:
NCI PharmGKB FDA

Alternate Names:

AMPHETAMINE Primary Drug Name

Drug Info:

Year of Approval approved before 1982

Drug Class central nervous system stimulants

Drug Info:

Drug Indications for treatment of cognitive dysfunction,for treatment of ADHD

Drug Class Small Molecule

FDA Approval approved

Alternate Names:

C28822 NCI drug code

Alternate Names:

D05BMG TTD Drug ID